Sickle Cell Disease clinical trials near you

8 shown of 138

8 shown of 138 clinical trials.

1. RecruitingObservationalNCT06887907

   Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

   Sickle Cell Disease (SCD)

   Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.

   Sites

   1

   Target

   40

   Study sites

   Toulouse, FR

   Sponsor: University Hospital, Toulouse

   View on ClinicalTrials.gov(opens in a new tab) Express interest
2. RecruitingInterventionalNCT06735625

   Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"

   in Relation to Sickle Cell Disease

   Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients

   Sites

   1

   Target

   100

   Study sites

   Saint-Denis, FR

   Sponsor: Centre Hospitalier de Saint-Denis

   View on ClinicalTrials.gov(opens in a new tab) Express interest
3. RecruitingInterventionalNCT06139510

   Predictors of Pain in Sickle Cell Disease

   Sickle Cell Disease, Chronic Pain

   Sickle cell disease is a painful inherited disorder that affects approximately 100,000 people in the United States, and more than half of these individuals develop chronic or persistent pain that is often severe and disabling. The factors that predict whether an individual with sickle cell disease will develop severe, disabling pain are unclear. The goal of this project is to identify the factors that predict severe pain outcomes in individuals living with sickle cell disease in order to improve pain management strategies and guide future studies of non-opioid therapies for treatment of their pain. Participants who agree to enroll in this study will be asked to participate in a virtual and then an in-person study visit for their full initial study assessment. They will answer survey questions during the virtual visit, and will be asked to complete several types of standard testing to understand how their body handles pain during the in-person visit. After completing the virtual and in-person sessions, participants will receive text or electronic medical record messages with brief survey (will take less than 8 minutes to complete) on their pain experiences every three months until the study is completed (or up to 48 months for people who are enrolled at the beginning of the study).

   Sites

   1

   Target

   70

   Study sites

   Durham, US

   Sponsor: Duke University

   View on ClinicalTrials.gov(opens in a new tab) Express interest
4. RecruitingInterventionalNCT06529874

   Pressure Pain Tolerance in Relation to Balance and Strength in Children

   Sickle Cell Anemia

   Sickle cell disease (SCD) is the most frequent life-threatening genetic hemoglobinopathy in the world and occurs due to the synthesis of abnormal hemoglobin S (HbS).Cells with sickle cell hemoglobin are stiff and sticky. When they lose their oxygen, they form into the shape of a sickle or crescent. This can cause pain and tissue damage. Significant decrease in exercise capacity was seen in sickle cell anemic children. In the absence of a guidelines that can guide the prescription of exercise in SCD children. This study is a step for determine the forms of prescription of pain on the balance and muscle strength to build up in future studies a safety of physical exercises for children with sickle cell anemia and improve their functional abilities.

   Sites

   1

   Target

   80

   Study sites

   Giza, EG

   Sponsor: Adly A Adam

   View on ClinicalTrials.gov(opens in a new tab) Express interest
5. RecruitingInterventionalNCT06555939

   Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

   Sickle Cell Disease

   Adolescents and young adults with sickle cell disease (SCD) face challenges managing their illness and maintaining their well-being. This study proposes to test the feasibility and acceptability of a resilience-promoting intervention through a Collaborative Care Model. The primary goal is to determine with the resilience intervention (PRISM) is feasible and acceptable for adolescents and young adults with SCD. Exploratory outcomes include whether this intervention improves depression, anxiety, and pain interference.

   Sites

   1

   Target

   25

   Study sites

   Boston, US

   Sponsor: Boston Children's Hospital

   View on ClinicalTrials.gov(opens in a new tab) Express interest
6. RecruitingPhase 3InterventionalNCT05285917

   Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa

   Sickle Cell Anemia in Children, Sickle Cell Disease

   Sickle cell anemia (SCA) is among the world's most common and devastating blood disorders, affecting more than 300,000 newborns per year. Most infants with SCA are born in the low-resource settings of sub- Saharan Africa, where an estimated 50-90% will die before 5 years of age due to lack of early diagnosis and appropriate care. Hydroxyurea is a safe and effective once-daily oral medication that has become the standard of care for the treatment of children with SCA in high-resource settings. There is now a growing body of evidence to support the safety and clinical benefits of hydroxyurea for the treatment of SCA in sub-Saharan Africa. The requirement for frequent laboratory monitoring, uncertainties about appropriate, most effective dosing, and the concern for hematologic laboratory toxicities, however, will continue to limit widespread hydroxyurea utilization and real-world effectiveness. The investigators have recently developed and prospectively evaluated an individualized, pharmacokinetics-guided hydroxyurea dosing strategy for children with SCA that has demonstrated optimal clinical and laboratory benefits with minimal toxicity. In this research study, the investigators aim to extend this precision medicine approach to Africa.

   Sites

   1

   Target

   400

   Study sites

   Luanda, AO

   Sponsor: Brown University

   View on ClinicalTrials.gov(opens in a new tab) Express interest
7. RecruitingInterventionalNCT06757829

   Pulmonary Functions in Sickle Cell Disease: Response to Acu-TENS

   Sickle Cell Disease

   pulmonary complications are common in sickle cell disease patients. Respiratory training using inspiratory muscle trainer (IMT) is usually a good choice to improve these complications. Recently, acupuncture like transcutaneous electrical nerve stimulation (AC-tens) may also improve these complications.

   Sites

   1

   Target

   40

   Study sites

   Dokki, EG

   Sponsor: Cairo University

   View on ClinicalTrials.gov(opens in a new tab) Express interest
8. RecruitingObservationalNCT06213402

   RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)

   Sickle Cell Disease, Thalassemia, Hemolytic; Anemia, Hereditary, Due to Enzyme Disorder, Anemia Due to Membrane Defect, CDA, Sideroblastic Anemia, Constitutional Aplastic Anemia, Iron Metabolism Disorders, Hereditary Anemia

   Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation. Different medical entities classified as RADs by ORPHA classification are most of them chronic life threating disorders with many unmet needs for their proper clinical management creating an impact on European health systems. RADs present diagnostic challenges and their appropriate management requires from specialised multidisciplinary teams in Centers of expertise. Although there are some examples of well-established national registries on RADs in EU, the lack of recommendations for Rare disease registries implementation and the lack of standards for interoperability has led to the fragmentation or unavailability of data on prevalence, survival, main clinical manifestations or treatments in most of the European countries.

   Sites

   1

   Target

   32,564

   Study sites

   Barcelona, ES

   Sponsor: Hospital Universitari Vall d'Hebron Research Institute

   View on ClinicalTrials.gov(opens in a new tab) Express interest